On the relative safety of parenteral iron formulations - Wikidata - awgldk - TriplyDB

On the relative safety of parenteral iron formulations

On the relative safety of parenteral iron formulations

http://www.wikidata.org/entity/Q28262418

about

The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents Iron therapy for pre-operative anaemia Iron therapy for pre-operative anaemia Role of iron supplementation to erythropoiesis stimulating agents in the management of chemotherapy-induced anemia in cancer patients Safety concerns about intravenous iron therapy in patients with chronic kidney disease Safety of intravenous iron formulations: facts and folklore Clinical Translation of Nanomedicine.Ferumoxytol for the treatment of iron deficiency.Data mining of the public version of the FDA Adverse Event Reporting System Is low-molecular weight iron dextran really the most risky iron?--Unconvincing data from an unconvincing study.Comparison of the renal, cardiovascular and hepatic toxicity data of original intravenous iron compounds.Parenteral iron formulations differentially affect MCP-1, HO-1, and NGAL gene expression and renal responses to injury.Diagnosis and management of iron deficiency anemia in patients with IBD.Efficacy and safety of IV ferumoxytol for adults with iron deficiency anemia previously unresponsive to or unable to tolerate oral iron Iron therapy for renal anemia: how much needed, how much harmful?Relative Incidence of Acute Adverse Events with Ferumoxytol Compared to Other Intravenous Iron Compounds: A Matched Cohort Study.Intravenous iron dextran as a component of anemia management in chronic kidney disease: a report of safety and efficacy.Parenteral iron with erythropoiesis-stimulating agents for chemotherapy-induced anemia.Safety issues with intravenous iron products in the management of anemia in chronic kidney disease Safety of intravenous iron use in chronic kidney disease.Best practices in cancer nanotechnology: perspective from NCI nanotechnology alliance.Safety profiles of total dose infusion of low-molecular-weight iron dextran and high-dose iron sucrose in renal patients.Diagnosis and treatment of cancer-related anemia.Hypersensitivity to intravenous iron: classification, terminology, mechanisms and management Diagnosis, Treatment, and Prevention of Hemodialysis Emergencies.The available intravenous iron formulations: History, efficacy, and toxicology.What are the Considerations in Balancing Benefits and Risks in Iron Treatment?: Balancing Benefits and Safety with Intravenous Iron Treatment.Effect of treatment with single total-dose intravenous iron versus daily oral iron(III)-hydroxide polymaltose on moderate puerperal iron-deficiency anemia Acute, severe and anaphylactoid reactions are very rare with low-molecular-weight iron dextran, CosmoFer.Safety and efficacy of rapid (1,000 mg in 1 hr) intravenous iron dextran for treatment of maternal iron deficient anemia of pregnancy.Update on adverse drug events associated with parenteral iron.The comparative safety of various intravenous iron preparations in chronic kidney disease patients.Acute hypersensitivity reaction to ferric gluconate in a premedicated patient.Comparative Evaluation of U.S. Brand and Generic Intravenous Sodium Ferric Gluconate Complex in Sucrose Injection: In Vitro Cellular Uptake.Practical considerations for iron therapy in the management of anaemia in patients with chronic kidney disease.Intravenous low molecular weight iron dextran in children with iron deficiency anemia unresponsive to oral iron.How to select a nanosimilar.Evaluation of the safety of iron dextran with parenteral nutrition in the paediatric inpatient setting.Medication practice in hospitals: are nanosimilars evaluated and substituted correctly?Practical guidance for the management of iron deficiency in patients with inflammatory bowel disease.

P2860

Q24186166-D8F77EA1-9478-45E0-9535-62F5FBC554D7 Q24186952-AE1EB9AE-9CB7-4328-99A0-B98AC67E7DFE Q24186979-595E08EE-9812-4B09-B6D4-EFA2095BC290 Q24203798-B028F164-F446-4962-B142-777A8F58C264 Q26764881-0287F844-CD32-43E8-8186-89C4CA7E5982 Q26853397-B38A5BEA-2951-49FB-9C68-1F95C25D1B21 Q30355939-DC9FCBEC-FDEB-43FC-AEB6-162905AD6158 Q30454001-576737ED-E337-4276-A025-39D1D8A9C28C Q30651235-26C5B2FC-6F1F-44D7-82A7-777CDC23C78B Q31045009-1CC40AE9-B98C-4545-9776-005F977150C8 Q33583025-C6AF6D7E-ED42-4A75-BA8B-F5577B76D7E2 Q34085240-069ADDF4-97B5-45A4-93BC-1C0DE48A3130 Q34141999-36D4A681-3C53-4D9E-95A2-CF2ABBBACA09 Q34470847-1C234513-4656-42A3-8848-886ED76463B3 Q35650627-895CEEDF-111F-4FBE-A516-F5010625ED0E Q36263980-05001EE1-0C91-45DD-A1B8-3461D01CAEE8 Q36734021-87C86F86-E5B4-4B72-8705-EB03BAEB56BE Q37109136-E0EC3650-A899-4614-9878-581F21FE27A8 Q37161960-1FB9E693-0C9F-40FA-897C-C5E40257C585 Q37320585-013A38FB-14FB-4480-8914-2079ECBD0438 Q37561973-BCC68483-4949-4298-8C45-FF36BCD455C5 Q37874704-FB12C0D8-8110-41C5-996F-29949F83C160 Q38188501-5A38669B-BD71-4891-A1F9-2D890C7BCF14 Q38564991-6F0C2158-FA7D-4024-8CA4-7AA797C9B8B1 Q38796784-712F1F0F-48A9-4031-93CC-265A3DE99E54 Q39216462-B84729F8-A048-4A94-A31B-CEA875AF940C Q40526919-F61E66DD-29CC-4F81-A8CE-114ECE48B269 Q40988215-33D7CB04-DC88-4C8E-BAF5-485869F4D3B7 Q42682575-07E5F18D-7A8D-4659-87FD-48009D5FA7C8 Q45029379-885B7397-21FD-45FC-A165-5F676BC0B07E Q46212164-4506D5CC-57BD-4555-8D6A-477E7CF6B7EE Q46459696-64C6F7F2-8CA5-4358-A168-7504A23F8D70 Q46803781-5CB3E9EC-686A-47F1-8A8F-0C34097EA66F Q47103693-F858CDD1-7581-480C-A18F-13D2FCC30A68 Q47129994-B24BAF2B-5B6E-4BC2-93EB-6DB3AE71F7DF Q47224814-EA92BCC4-7FD6-4BBF-9085-066C0902ED7E Q47762210-2B3D67A9-362D-4292-9D60-9B95A316B97C Q48322013-6F47CA86-7F1F-47D4-A9E2-DCC4D78A34E2 Q52337431-5F98314D-DDAD-489D-8D90-8CD9D9BFF456 Q54211926-B76BB7D0-B06D-4553-9A4A-C2B3548441B4

P2860

On the relative safety of parenteral iron formulations

http://www.wikidata.org/entity/Q28262418

description

2004 nî lūn-bûn

@nan

2004 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

On the relative safety of parenteral iron formulations

@ast

On the relative safety of parenteral iron formulations

@en

On the relative safety of parenteral iron formulations

@nl

type

label

On the relative safety of parenteral iron formulations

@ast

On the relative safety of parenteral iron formulations

@en

On the relative safety of parenteral iron formulations

@nl

prefLabel

On the relative safety of parenteral iron formulations

@ast

On the relative safety of parenteral iron formulations

@en

On the relative safety of parenteral iron formulations

@nl

P1433

Q28262418-CD9AA6CC-E9E0-4476-ADDA-30B1C41379D0

P1476

Q28262418-2942F267-4C12-489B-A90C-6E67EF5F53FE

P2093

Q28262418-4D8102B5-6112-4586-85DF-CDE8B3135749

Q28262418-959B66B4-3B25-4FC8-A31F-263B584B2B40

Q28262418-A130F2EC-A563-4400-B760-61D8F86E1D3E

Q28262418-F0A824A6-8B8C-4E6B-80DE-F85D951A4737

P2860

Q28262418-27F12660-5954-44DA-B839-D3F42FEAB08D

Q28262418-48A33300-30C3-4F7E-849B-998E99EF9AD6

Q28262418-5EA6756B-0734-4D41-9B17-A7210B55E642

Q28262418-70A36141-2C27-4416-99FB-B7C572D70FE6

Q28262418-7BFDC924-9DD5-4F6E-9462-DC8B57C738D9

Q28262418-88396F72-0395-4640-80E3-BE9A100532C1

Q28262418-94A37219-8E30-44BF-9F9F-F73AC2539B43

Q28262418-A0B2FA90-AE61-4281-AC9A-A6DFE6DA69EA

Q28262418-ADC52DF3-E926-4DCC-9007-05FE9B7AC2BB

Q28262418-B2D292D8-3CF3-4752-A640-F27131B399CF

P304

Q28262418-24C756E8-95FB-40F3-B199-D0E145D2DB5B

P31

Q28262418-5E2B2BB2-D69E-4575-84FB-EE1F8FF83487

P3181

Q28262418-965F4170-2C03-4021-B65D-5CFCFC1E2819

P356

Q28262418-1564BBDA-57DB-475A-8B0C-111DE8C8902D

P407

Q28262418-BF7303A7-D1AD-4368-B72F-E3D71374E4F2

P433

Q28262418-BBF93640-2738-496E-8218-D326E0A2D217

P478

Q28262418-3D8AABC4-5BB4-4116-9660-78FBDA33985C

P577

Q28262418-41B4FE2E-BF6C-4C55-9542-BC7046B0DA90

P5875

Q28262418-757222A7-B5F0-4CF3-A113-9082CA79A59F

P698

Q28262418-C9856C85-8CEF-4855-BCB9-482DD1520067

P3181

P356

P1433

Nephrology Dialysis Transplantation

P1476

On the relative safety of parenteral iron formulations

@en

P2093

Glenn M Chertow

http://www.w3.org/2001/XMLSchema#string

Jarl Ahlmén

http://www.w3.org/2001/XMLSchema#string

Odd Vaage-Nilsen

http://www.w3.org/2001/XMLSchema#string

Phillip D Mason

http://www.w3.org/2001/XMLSchema#string

P2860

Timing of new black box warnings and withdrawals for prescription medications

Sodium ferric gluconate complex in sucrose: safer intravenous iron therapy than iron dextrans.

The comparative safety of intravenous iron dextran, iron saccharate, and sodium ferric gluconate.

Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compared to placebo and iron dextran.

Parenteral iron formulations: a comparative toxicologic analysis and mechanisms of cell injury.

Adverse events in chronic hemodialysis patients receiving intravenous iron dextran--a comparison of two products.

The safety of intravenous iron dextran in hemodialysis patients.

Confidence intervals for the odds ratio in case-control studies: the state of the art.

A randomized, controlled parallel-group trial on efficacy and safety of iron sucrose (Venofer) vs iron gluconate (Ferrlecit) in haemodialysis patients treated with rHuEpo.

Suspected iron dextran-related adverse drug events in hemodialysis patients.

P304

1571-5

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3932645

http://www.w3.org/2001/XMLSchema#string

P356

10.1093/NDT/GFH185

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P577

2004-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8556610

http://www.w3.org/2001/XMLSchema#string

P698

15150356

http://www.w3.org/2001/XMLSchema#string